Zydus Lifesciences has informed that it enclosed a copy of press release dated May 4, 2024 titled ‘Sentynl Therapeutics announces global acquisition of Zokinvy® (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals’.
The above information is a part of company’s filings submitted to BSE.